Charlie Zhou: Exploring the Potential of Immune Reset Therapies in Autoimmune Cytopenias
Charlie Zhou, Head of Portfolio Strategy at Ouro Medicines, shared a post on LinkedIn about the recent article he and his colleagues co-authored, adding:
“It’s been a privilege to collaborate with some of the preeminent experts in autoimmune cytopenias on this review examining the potential of immune reset therapies to change the treatment landscape for these debilitating conditions.”
Title: Towards achieving immune reset in autoimmune cytopenias: Insights from clinical experiences with B cell depleting therapies
Authors: David J. Kuter, Sigbjørn Berentsen, Nichola Cooper, Lei Zhang, Jun Shi, Yunfei Chen, Lele Zhang, Charlie Zhou, Yanrong Wang, Jaideep S. Dudani, Neelufar Mozaffarian
Read the Full Article on Blood Reviews
Stay updated with Hemostasis Today.
-
Aug 11, 2026, 08:07Nicola Pozzi: Advancing Hemostasis Through Scientific Collaboration at Hemostasis GRC
-
Aug 11, 2026, 07:50When Access to Care Changes Everything – WFH
-
Aug 11, 2026, 07:41Kevin Land: How Cellular Therapy Is Changing Transfusion Medicine
-
Aug 11, 2026, 07:35Kuldeep Singh Bhadauria: Building the Future of Hemophilia Care in India
-
Aug 11, 2026, 07:28Archil Jaliashvili: When Every Minute Matters Time Becomes a Therapy
-
Aug 11, 2026, 07:05Mavis Agnes Kisakye: Building Sustainable Transition Pathways in Hemophilia Care
-
Aug 11, 2026, 06:48Rishdha Roshad: What Happens to the Brain During Cardiopulmonary Bypass?
-
Aug 11, 2026, 05:53Isaac Okello: Strengthening Sickle Cell Advocacy in Uganda
-
Aug 11, 2026, 05:38Rami Unterman: A Simple New Biomarker for Fibrotic ILDs